Rasilez® reduces left ventricular hypertrophy, a powerful predictor of heart disease
|
01 April 2008 |
Femara® helps protect against return of breast cancer
|
12 March 2008 |
Novartis Vaccines Institute for Global Health (NVGH) is the first institute with nonprofit mission
|
25 February 2008 |
Novartis achieves record results in 2007 underscoring benefits of strategic healthcare portfolio
|
21 January 2008 |
Galvus®, a new oral treatment for type 2 diabetes, receives positive opinion
|
20 December 2007 |
Novartis further strengthens biologics capabilities in expansion of MorphoSys collaboration
|
05 December 2007 |
Novartis withdraws its application to extend the marketing authorisation for Zometa
|
21 November 2007 |
Menveo(TM) (MenACWY-CRM) vaccine to demonstrate an excellent immune response in infants
|
19 November 2007 |
Tasigna® receives US approval providing new hope to chronic myeloid leukemia patients
|
02 November 2007 |
Novartis delivers record earnings in first nine months of 2007
|
20 October 2007 |